Lenvatinib in Elderly Patients — and Those With Other Illnesses

Age alone does not determine whether lenvatinib is appropriate. The clinical trials that supported lenvatinib's approval enrolled patients across a wide age range, and ESMO and NCCN guidance does not set an upper age cutoff. What matters is your functional status — how your heart, kidneys, liver and general fitness are holding up — and whether those are stable enough to tolerate the treatment. Older patients are more likely to need dose adjustments or more frequent monitoring, but many are treated successfully.

Possibly. Lenvatinib raises blood pressure in a proportion of patients, so if you are already taking antihypertensives, your dose may need to go up or an additional agent may be added. Some blood pressure medicines also interact with lenvatinib's metabolism, so your team will review what you are taking before you start. Do not add or stop any blood pressure medicine without telling your oncology team — even if your GP suggests a change, both teams need to know.

In most cases, yes, but the dose is adjusted. The approved prescribing information specifies a dose reduction for severe renal impairment. Your team will also monitor urine protein throughout treatment, because lenvatinib can increase protein loss through the kidneys — something to manage carefully when they are already under strain. The important thing is to be clear about your current kidney function before the first dose so the right starting dose is chosen from the outset.

It can. Lenvatinib is used to treat hepatocellular carcinoma, often in patients who also have cirrhosis or chronic hepatitis. The prescribing information includes dose guidance based on liver function classification. Your oncologist will assess your liver reserve — how much functional tissue remains — before starting. Liver function tests are monitored regularly throughout treatment because both the disease and the medicine affect the liver, and changes need to be caught promptly.

Usually yes, but your diabetes management may need adjusting once treatment starts, because lenvatinib can affect blood glucose. If you take metformin or other oral medicines, your team will likely review them at the outset. If you use insulin, more frequent glucose monitoring may be needed in the early weeks. Make sure your oncologist and the doctor who manages your diabetes are in communication — a change in one medicine can shift the other out of balance.

Your oncologist will decide based on your history. If you have pre-existing heart disease, a history of irregular heartbeat, or risk factors for cardiac problems, an ECG or echocardiogram may be requested before treatment begins. Lenvatinib can affect cardiac electrical activity and heart muscle function, so a baseline measurement is useful for comparison if symptoms develop later. This is standard caution, not a sign that lenvatinib is unsuitable for you.

Your oncologist will reassess the risk-benefit balance. For problems that lenvatinib itself is causing — such as blood pressure that becomes hard to control — the standard approach is dose reduction or a temporary hold rather than stopping permanently. For unrelated deterioration in a pre-existing condition, the decision involves the specialist managing that condition as well. Neither team should make major changes without the other knowing. If you are admitted to hospital for any reason, make sure the admitting team knows you are on lenvatinib.

Not automatically. Lenvatinib dosing is based primarily on the cancer type being treated and on organ function, not on age. A fit older patient with good kidney and liver function may start at the same dose as a much younger person. Where age matters is at the threshold for adjustment: older or frailer patients may be more sensitive to side effects, and some oncologists prefer a cautious early approach. Ask your oncologist what dose they are starting you on and why — that is a reasonable question to put directly.